消瘤芥(AT-1258,Nitrocaphane)是我国创制的一种抗癌新药。它是在研究一系列甲基氮芥衍生物过程中总结抗瘤新芥(AT-581,Ocaphane)的研究基础上发展而得的。通过实行科研、临床和生产三结合,完成化学和药理研究后,于1969年推荐临床。经8个省市28个临床单位试用后证明,对肺癌、鼻咽癌、子宫颈癌、乳腺癌和恶性淋巴瘤等有较好的治疗作用。现将其化学、药理研究及临床结果介绍如下: The tumor-bearing mustard (AT-1258, Nitrocaphane) is an anti-cancer drug created in China. It was developed on the basis of a study of a series of methyl nitrogen mustard derivatives during the study of the new anti-tumor mustard (AT-581, Ocaphane). After the completion of the chemical and pharmacological studies through the implementation of a combination of scientific research, clinical practice and production, clinical practice was recommended in 1969. After trials in 28 clinical units in 8 provinces and cities, it proved that it has a good therapeutic effect on lung cancer, nasopharyngeal carcinoma, cervical cancer, breast cancer, and malignant lymphoma. Its chemical and pharmacological research and clinical results are now described as follows: